Edgewise Therapeutics (EWTX) Share-based Compensation (2020 - 2026)
Edgewise Therapeutics has reported Share-based Compensation over the past 7 years, most recently at $8.7 million for Q1 2026.
- Quarterly results put Share-based Compensation at $8.7 million for Q1 2026, down 3.8% from a year ago — trailing twelve months through Mar 2026 was $34.4 million (up 19.06% YoY), and the annual figure for FY2025 was $34.8 million, up 40.63%.
- Share-based Compensation reached $8.7 million in Q1 2026 per EWTX's latest filing, down from $9.9 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $9.9 million in Q4 2025 and bottomed at $2.0 million in Q1 2022.
- Median Share-based Compensation over the past 5 years was $5.2 million (2023), compared with a mean of $5.7 million.
- The largest annual shift saw Share-based Compensation surged 568.24% in 2022 before it decreased 3.8% in 2026.
- Over 5 years, Share-based Compensation stood at $3.7 million in 2022, then surged by 37.93% to $5.2 million in 2023, then surged by 50.15% to $7.7 million in 2024, then rose by 27.63% to $9.9 million in 2025, then decreased by 11.75% to $8.7 million in 2026.
- Business Quant data shows Share-based Compensation for EWTX at $8.7 million in Q1 2026, $9.9 million in Q4 2025, and $8.1 million in Q3 2025.